Compare ENTX & JYNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENTX | JYNT |
|---|---|---|
| Founded | 2010 | 2010 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Multi-Sector Companies |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.0M | 149.5M |
| IPO Year | 2018 | 2014 |
| Metric | ENTX | JYNT |
|---|---|---|
| Price | $2.37 | $8.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $10.00 | ★ $17.00 |
| AVG Volume (30 Days) | 107.9K | ★ 139.7K |
| Earning Date | 11-14-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $124,000.00 | ★ $54,176,002.00 |
| Revenue This Year | N/A | $7.70 |
| Revenue Next Year | N/A | $10.24 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 25.25 | 10.47 |
| 52 Week Low | $1.50 | $7.50 |
| 52 Week High | $3.22 | $13.47 |
| Indicator | ENTX | JYNT |
|---|---|---|
| Relative Strength Index (RSI) | 39.09 | 47.79 |
| Support Level | $2.26 | $8.18 |
| Resistance Level | $2.53 | $8.64 |
| Average True Range (ATR) | 0.23 | 0.29 |
| MACD | -0.07 | 0.06 |
| Stochastic Oscillator | 6.05 | 64.24 |
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has one operating business segment; The Franchise Operations segment which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the Company's franchise license, which represents symbolic intellectual property.